Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Regeneron Pharmaceuticals Inc., EBITDA calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income 4,412,600 3,953,600 4,338,400 8,075,300 3,513,200
Add: Income tax expense 367,300 245,700 520,400 1,250,500 297,200
Earnings before tax (EBT) 4,779,900 4,199,300 4,858,800 9,325,800 3,810,400
Add: Interest expense 55,200 73,000 59,400 57,300 56,900
Earnings before interest and tax (EBIT) 4,835,100 4,272,300 4,918,200 9,383,100 3,867,300
Add: Depreciation and amortization 482,900 421,000 341,400 286,200 235,900
Earnings before interest, tax, depreciation and amortization (EBITDA) 5,318,000 4,693,300 5,259,600 9,669,300 4,103,200

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. Regeneron Pharmaceuticals Inc. EBITDA decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Enterprise Value to EBITDA Ratio, Current

Regeneron Pharmaceuticals Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV) 69,784,067
Earnings before interest, tax, depreciation and amortization (EBITDA) 5,318,000
Valuation Ratio
EV/EBITDA 13.12
Benchmarks
EV/EBITDA, Competitors1
AbbVie Inc. 27.92
Amgen Inc. 15.59
Bristol-Myers Squibb Co. 7.27
Danaher Corp. 22.34
Eli Lilly & Co. 56.36
Gilead Sciences Inc. 14.75
Johnson & Johnson 16.00
Merck & Co. Inc. 36.17
Pfizer Inc. 21.58
Thermo Fisher Scientific Inc. 19.89
Vertex Pharmaceuticals Inc. 24.52
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 23.04
EV/EBITDA, Industry
Health Care 19.49

Based on: 10-K (reporting date: 2024-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.

Enterprise Value to EBITDA Ratio, Historical

Regeneron Pharmaceuticals Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1 72,047,086 94,631,456 80,327,035 64,555,508 52,128,277
Earnings before interest, tax, depreciation and amortization (EBITDA)2 5,318,000 4,693,300 5,259,600 9,669,300 4,103,200
Valuation Ratio
EV/EBITDA3 13.55 20.16 15.27 6.68 12.70
Benchmarks
EV/EBITDA, Competitors4
AbbVie Inc. 26.97 20.79 13.31 13.44 21.34
Amgen Inc. 15.31 14.13 12.97 13.22 12.24
Bristol-Myers Squibb Co. — 6.51 9.46 8.65 34.35
Danaher Corp. 22.34 26.41 18.42 21.05 26.68
Eli Lilly & Co. 55.98 85.33 37.74 29.85 23.67
Gilead Sciences Inc. — 10.41 13.89 8.57 24.90
Johnson & Johnson 15.77 16.45 14.78 14.47 18.20
Merck & Co. Inc. — 51.30 13.91 12.18 16.05
Pfizer Inc. — 22.50 6.12 8.64 15.78
Thermo Fisher Scientific Inc. 19.89 21.83 20.25 20.21 18.72
Vertex Pharmaceuticals Inc. — 21.57 14.91 18.92 14.81
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences — 22.59 13.58 13.16 18.90
EV/EBITDA, Industry
Health Care — 18.98 13.71 13.87 16.50

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 See details »

2 See details »

3 2024 Calculation
EV/EBITDA = EV ÷ EBITDA
= 72,047,086 ÷ 5,318,000 = 13.55

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/EBITDA Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. Regeneron Pharmaceuticals Inc. EV/EBITDA ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.